1. Home
  2. QURE vs MESO Comparison

QURE vs MESO Comparison

Compare QURE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$22.82

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$17.49

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QURE
MESO
Founded
1998
2004
Country
Netherlands
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
QURE
MESO
Price
$22.82
$17.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
2
Target Price
$58.55
$24.00
AVG Volume (30 Days)
2.0M
210.4K
Earning Date
02-26-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,751,000.00
$17,198,000.00
Revenue This Year
N/A
$576.59
Revenue Next Year
$142.93
$41.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
191.39
52 Week Low
$7.76
$9.61
52 Week High
$71.50
$21.50

Technical Indicators

Market Signals
Indicator
QURE
MESO
Relative Strength Index (RSI) 44.78 43.82
Support Level $21.15 $17.38
Resistance Level $28.77 $18.02
Average True Range (ATR) 1.60 0.67
MACD 0.23 -0.27
Stochastic Oscillator 21.85 3.49

Price Performance

Historical Comparison
QURE
MESO

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: